+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Companion Diagnostics: Technologies and Global Market 2021-2026

  • ID: 5416606
  • Report
  • September 2021
  • Region: Global
  • BCC Research
UP TO OFF until May 31st 2022

FEATURED COMPANIES

  • Abbott Laboratories Inc.
  • Asuragen Inc.
  • Cerba Research
  • Foundation Medicine Inc.
  • Invivoscribe, Inc.
  • Qiagen Gmbh

The global market for companion diagnostics (CDx) is estimated to grow from $5.4 billion in 2021 to reach $10.7 billion by 2026, at a compound annual growth rate (CAGR) of 14.6% during the forecast period of 2021-2026.




The global market for NGS-CDx (next-generation sequencing) is estimated to grow from $1.3 billion in 2021 to reach $3.3 billion by 2026, at a CAGR of 20.9% during the forecast period of 2021-2026.


The global market for PCR-CDx (polymerase chain reaction) is estimated to grow from $762.0 million in 2021 to reach $1.6 billion by 2026, at a CAGR of 15.3% during the forecast period of 2021-2026.


Report Scope

This report provides a comprehensive analysis of the CDx market in the global context, including market forecasts and sales through 2026. The report analyzes the market by segmenting it into the various product offerings: consumables (reagents, kits and panels), services and software. The segmentation also provides analysis by popular technology types such as PCR, next-generation sequencing, in situ hybridization (ISH), immunohistochemistry (IHC) and others.


This study surveys the CDx market by application into different therapeutic areas. The market is also assessed in three major geographic regions: North America, Europe and Asia-Pacific (APAC). The APAC markets include countries like India, China, Korea, Japan, Taiwan, Australia and New Zealand.


The report features new product developments, clinical trials and patents boosting the growth of this market in the global context.


This report provides comprehensive profiles of market players in the industry. The industry structure chapter focuses on the changing market trends, market players and their leading products. This chapter also covers the mergers and acquisitions and any other collaborations or partnerships that happened during the evaluation period of this report that are expected to shape the industry.


Factors such as strengths, weaknesses, threats and opportunities that are expected to play a role in this market are evaluated in detail.


The scope of the report excludes the in vitro diagnostic products and their regulatory aspects. Also excluded are the nucleic acid-based tests in general, focusing solely on the companion diagnostics that meet the FDA definition.


The Report Includes

  • 53 data tables and 44 additional tables
  • An overview of the global market for companion diagnostic (CDx) technologies
  • Analyses of the global market trends, with data from 2019-2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026
  • Evaluation of current market size, market forecast, and technological advancements within the industry and discussion on technical issues related to biomarker stability and storage
  • Market share analysis of global CDx market by solution and type of test, technology, application, and geographic region
  • Information on biomarkers, their role in precision medicine and discussion on the potential use of biomarkers in the development of companion diagnostics (CDx)
  • Insights into CDx approvals and FDA guidelines for new drugs and description of predictive genomic biomarkers for immunotherapy including microsatellite instability (MSI) and tumor mutational burden (TMB)
  • Coverage of new CDx product developments, clinical trials, patents issued, mergers and acquisitions, partnerships, collaborations and other effective market development strategies
  • Comprehensive company profiles of major industry players, including Adaptive Biotechnologies, Exact Sciences Corp., Exosome Diagnostics Inc., Foundation Medicine Inc., Myriad Genetic Laboratories Inc., Roche Molecular Systems Inc., Prometheus Biosciences, Qiagen and Thermo Fisher Scientific Inc.
Frequently Asked Questions about the Global Companion Diagnostics Market

What is the estimated value of the Global Companion Diagnostics Market?

The Global Companion Diagnostics Market was estimated to be valued at $5.4 Billion in 2021.

What is the growth rate of the Global Companion Diagnostics Market?

The growth rate of the Global Companion Diagnostics Market is 14.6%, with an estimated value of $10.7 Billion by 2026.

What is the forecasted size of the Global Companion Diagnostics Market?

The Global Companion Diagnostics Market is estimated to be worth $10.7 Billion by 2026.

Who are the key companies in the Global Companion Diagnostics Market?

Key companies in the Global Companion Diagnostics Market include Abbott Laboratories Inc., Abnova Corp., Adaptive Biotechnologies Corp., Advanced Cell Diagnostics Inc., Agilent Technologies Inc., Almac Group Ltd., Amoy Diagnostics Co., Ltd., Arup Laboratories and Autogenomics Inc. (Acquired By Prescient Medicine).
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories Inc.
  • Asuragen Inc.
  • Cerba Research
  • Foundation Medicine Inc.
  • Invivoscribe, Inc.
  • Qiagen Gmbh

Chapter 1 Introduction
  • Study Goals and Objectives
  • Reasons for Doing This Study
  • What's New in This Update?
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Custom Research
  • Related Reports


Chapter 2 Summary and Highlights
  • Summary
  • Key Highlights


Chapter 3 Market and Technology Background
  • Personalized Medicine and Biomarkers
  • Predictive Biomarkers
  • Companion Diagnostics and Complementary Diagnostics
  • Companion Diagnostic Development
  • CDx Stakeholders
  • Technologies Used in CDx
  • Applications of CDx
  • Regulatory Aspects of CDx


Chapter 4 Market Breakdown by Solution and Type of Test
  • Global Market for Companion Diagnostic by Type of Test
  • Market Overview
  • Global Market for Companion Diagnostics by Solution
  • Market Overview
  • Global Market for Companion Diagnostic Solutions by Region
  • Instruments
  • Consumables
  • Services


Chapter 5 Market Breakdown by Technology
  • Global Market for Companion Diagnostics by Technology
  • Market Overview
  • Global Market for Companion Diagnostic Technologies by Region
  • Market Shares
  • Immunohistochemistry
  • In Situ Hybridization
  • Polymerase Chain Reaction
  • Next-Generation Sequencing
  • Genotyping
  • Others
  • CDx Development Services


Chapter 6 Market Breakdown by Application
  • Global Market for Companion Diagnostic Applications
  • Market Overview
  • Global Market for Companion Diagnostic Applications by Region
  • Market Shares
  • Cancer
  • Pharmacogenetics
  • Cystic Fibrosis
  • HIV
  • LDT-CDx by Application
  • CDx in Non-oncology Areas


Chapter 7 Industry Structure
  • Stakeholders in Companion Diagnostics
  • Driving Trends in Companion Diagnostics
  • Business Models of Companion Diagnostics
  • Grants and Funding in Companion Diagnostics
  • Collaborations and Partnerships
  • Mergers and Acquisitions
  • Leading Market Players in Companion Diagnostics Market
  • Leading Market Players in IHC Market
  • Leading Market Players in ISH Market
  • Leading Market Players in PCR Market
  • Leading Market Players in NGS Market
  • Leading Market Players in Genotyping Market
  • Leading Market Players in Other CDx Technologies Market


Chapter 8 Patent Review
  • Patents in Companion Diagnostics Market
  • Patent Analysis
  • Patents by Year
  • Patents by Application
  • Patents by Company
  • Patents by Country
  • Patents by Assignee


Chapter 9 Clinical Trials Analysis
  • Clinical Trials and CDx
  • Clinical Trials Analysis
  • Clinical Trials Analysis by Type of Study
  • Clinical Trials Analysis by Status
  • Clinical Trials Analysis by Phase
  • Clinical Trials Analysis by Technology
  • Clinical Trial Analysis by Application
  • Clinical Trial Analysis by Therapeutic Area
  • Companies with Companion Diagnostics in Clinical Trials


Chapter 10 Analysis of Market Opportunities
  • Market Dynamics
  • Strengths
  • Challenges
  • Opportunities
  • Threats


Chapter 11 Company Profiles
  • Abbott Laboratories Inc.
  • Abnova Corp.
  • Adaptive Biotechnologies Corp.
  • Advanced Cell Diagnostics Inc.
  • Agilent Technologies Inc.
  • Amoy Diagnostics Co., Ltd.
  • Almac Group Ltd.
  • Arup Laboratories
  • Asuragen Inc.
  • Autogenomics Inc. (Acquired By Prescient Medicine)
  • Biocartis Nv
  • Biodesix, Inc.
  • Biofluidica
  • Biomerieux Sa
  • Cerba Research
  • Circulogene
  • Clinical Micro Sensors Inc. (Now Genmark Diagnostics Inc.)
  • Exact Sciences Corp.
  • Exosomedx, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Foundation Medicine Inc.
  • Guardant Health Inc.
  • Hologic Inc.
  • Icon Plc
  • Illumina Inc.
  • Invivoscribe, Inc.
  • Leica Biosystems (Division Of Leica Microsystems Inc.)
  • Luminex Molecular Diagnostics Inc. (Luminex Corp.)
  • Maze Therapeutics
  • Monogram Biosciences Inc. (Part Of Labcorp)
  • Myriad Genetics Inc.
  • Neogenomics Laboratories
  • Prometheus Biosciences
  • Qiagen Gmbh
  • Quest Diagnostics Inc.
  • Resolution Bioscience Inc.
  • Resonance Health Ltd.
  • Siemens Healthineers Ag
  • Spartan Bioscience Inc.
  • Sysmex Corp.
  • Thermo Fisher Scientific Inc.
  • Trimgen Corp.
  • Vela Diagnostics Inc.


Chapter 12 Appendix: Acronyms
List of Tables
Summary Table: Global Market for Companion Diagnostics, by Technology, Through 2026
Table 1: Examples of Predictive Biomarkers
Table 2: Biomarkers Used in Companion Diagnostics
Table 3: Commercial CDx vs. LDT-CDx
Table 4: Examples of Technologies Used in Different CDx
Table 5: FDA List of Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations
Table 6: Different Agents Used for Chemotherapy and Targeted Therapy
Table 7: Comparison between Chemotherapy and Targeted Therapy
Table 8: Differences between PMA, HDE and 510(k) Applications for CDx
Table 9: CLIA Categorization Criteria
Table 10: Regulatory Approvals Granted for CDx
Table 11: Global Market for Companion Diagnostics, by Type of Test, Through 2026
Table 12: Global Market Shares of Companion Diagnostics, by Type of Test, 2020
Table 13: Global Market for Companion Diagnostics, by Solution, Through 2026
Table 14: Global Market Shares of Companion Diagnostics, by Solution, 2020
Table 15: Global Market for Companion Diagnostic Solutions, by Region, Through 2026
Table 16: Global Market Shares of Companion Diagnostic Solutions, by Region, 2020
Table 17: Global Market for Companion Diagnostic Instruments, by Region, Through 2026
Table 18: Global Market for Companion Diagnostic Consumables, by Region, Through 2026
Table 19: Global Market for Companion Diagnostic Services, by Region, Through 2026
Table 20: FDA-Approved CDx Technologies, by Year, 2000-June 2021
Table 21: Number and Percentage of FDA-Approved CDx Tests, by Technology, 2000-June 2021
Table 22: Global Market for Companion Diagnostics, by Technology, Through 2026
Table 23: Global Market Shares of Companion Diagnostics, by Technology, 2020
Table 24: Global Market for Companion Diagnostic Technologies, by Region, Through 2026
Table 25: Global Market Shares of Companion Diagnostic Technologies, by Region, 2020
Table 26: FDA-Approved IHC-CDx
Table 27: Global Market for Immunohistochemistry CDx, by Region, Through 2026
Table 28: FDA-Approved ISH-CDx
Table 29: Global Market for In Situ Hybridization CDx, by Region, Through 2026
Table 30: FDA-Approved PCR-CDx
Table 31: Global Market for Polymerase Chain Reaction CDx, by Region, Through 2026
Table 32: FDA-Approved NGS-CDx
Table 33: Foundation Medicine CDx Indications-Biomarkers
Table 34: Global Market for Next-Generation Sequencing CDx, by Region, Through 2026
Table 35: FDA-Cleared Pharmacogenetic Tests
Table 36: Global Market for Genotyping CDx, by Region, Through 2026
Table 37: Global Market for Other CDx Technologies, by Region, Through 2026
Table 38: Technological Expertise in CDx Services Sector
Table 39: Global Market for Companion Diagnostic Services, by Region, Through 2026
Table 40: Global Market for Companion Diagnostics, by Application, Through 2026
Table 41: Global Market Shares of Companion Diagnostics, by Application, 2020
Table 42: Global Market for Companion Diagnostic Applications, by Region, Through 2026
Table 43: Global Market Shares of Companion Diagnostic Applications, by Region, 2020
Table 44: Drugs with Approved Companion Diagnostics
Table 45: Global Market for Companion Diagnostics in Cancer Applications, by Region, Through 2026
Table 46: Total Number of Drugs with Approved CDx, by Cancer Type, 2018
Table 47: Global Market for Companion Diagnostics in Cancer Applications, by Cancer Type, Through 2026
Table 48: Global Market Shares of Companion Diagnostics in Cancer Applications, by Cancer Type, 2020
Table 49: Examples of Drugs with CYP450 Pharmacogenomic Biomarkers in Drug Labeling
Table 50: Examples of Drugs with Pharmacogenomic Biomarkers in Drug Labeling
Table 51: Global Market for Companion Diagnostics in Pharmacogenetic Applications, by Region, Through 2026
Table 52: Global Market for Companion Diagnostics in Cystic Fibrosis Applications, by Region, Through 2026
Table 53: Classes of ART
Table 54: Global Market for Companion Diagnostics in HIV Applications, by Region, Through 2026
Table 55: Global Market for LDT-CDx, by Application, Through 2026
Table 56: Grants and Funding in Companion Diagnostics, 2019-July 15th, 2020
Table 57: Collaborations and Partnerships in the Global Companion Diagnostics Market, 2018-July 15, 2020
Table 58: Mergers and Acquisitions in the Global Companion Diagnostics Market, 2018-July 15th, 2020
Table 59: Leading Developers of IHC Companion Diagnostics, 2020
Table 60: Global Market Shares of Leading Developers of IHC Companion Diagnostics, 2020
Table 61: Leading Developers of ISH Companion Diagnostics, 2020
Table 62: Global Market Shares of Leading Developers of ISH Companion Diagnostics, 2020
Table 63: Leading Developers of PCR Companion Diagnostics, 2020
Table 64: Global Market Shares of Leading Developers of PCR Companion Diagnostics, 2020
Table 65: Leading Developers of NGS Companion Diagnostics, 2020
Table 66: Global Market Shares of Leading Developers of NGS Companion Diagnostics, 2020
Table 67: Leading Developers of Genotyping Companion Diagnostics, 2020
Table 68: Global Market Shares of Leading Developers of Genotyping Companion Diagnostics, 2020
Table 69: Leading Developers of Other Companion Diagnostics, 2020
Table 70: Global Market Shares of Leading Developers of Other Companion Diagnostics, 2020
Table 71: Basic Aspects of Patents
Table 72: Representative Patents in Companion Diagnostics, 2018-June 2021
Table 73: Patents Issued for Companion Diagnostics, by Year, 2018-June 2021
Table 74: Patents Issued for Companion Diagnostics, by Application, 2018-June 2021
Table 75: Patents Issued for Companion Diagnostics, by Company, 2018-June 2021
Table 76: Patents Issued for Companion Diagnostics, by Country, 2018-June 2021
Table 77: Patents Issued for Companion Diagnostics, by Assignee, 2018-June 2021
Table 78: Clinical Trials in Companion Diagnostics, by Type of Study
Table 79: Clinical Trials in Companion Diagnostics, by Status
Table 80: Clinical Trials in Companion Diagnostics, by Phase
Table 81: Clinical Trials in Companion Diagnostics, by Technology
Table 82: Clinical Trials on Companion Diagnostics, by Application
Table 83: Clinical Trials in Companion Diagnostics, by Therapeutic Area
Table 84: Companies with CDx in Clinical Trials
Table 85: Companion Diagnostics and Approved Drugs, 2017-2020
Table 86: FoundationOne CDx Approved Indications
Table 87: Common Inefficiencies in Clinical Testing Landscape
Table 88: Initiatives Towards Harmonization of Commercial and LDT-CDx
Table 89: All of Us Research Program Highlights
Table 90: Foundation Medicine: List of Pipeline Companion Diagnostics
Table 91: Guardant Health: List of Pipeline Companion Diagnostics
Table 92: Myriad Genetics' List of Pipeline Companion Diagnostics
Table 93: Prometheus Biosciences' List of Pipeline Companion Diagnostics
Table 94: Qiagen GmbH's List of Pipeline Companion Diagnostics
Table 95: Thermo Fisher Scientific Inc.: List of Pipeline Companion Diagnostics
Table 96: Acronyms Used in This Report


List of Figures
Summary Figure: Global Market for Companion Diagnostics, by Technology, 2019-2026
Figure 1: Companion Diagnostic Co-development Process from Biomarker Discovery to Regulatory Approval
Figure 2: Global Market for Companion Diagnostics, by Type of Test, 2019-2026
Figure 3: Global Market Shares of Companion Diagnostics, by Type of Test, 2020
Figure 4: Global Market for Companion Diagnostics, by Solution, 2019-2026
Figure 5: Global Market Shares of Companion Diagnostics, by Solution, 2020
Figure 6: Global Market for Companion Diagnostic Solutions, by Region, 2019-2026
Figure 7: Global Market Shares of Companion Diagnostic Solutions, by Region, 2020
Figure 8: Global Market for Companion Diagnostic Instruments, by Region, 2019-2026
Figure 9: Global Market for Companion Diagnostic Consumables, by Region, 2019-2026
Figure 10: Global Market for Companion Diagnostic Services, by Region, 2019-2026
Figure 11: Share of FDA-Approved CDx Tests, by Technology, 2000-June 2021
Figure 12: Global Market for Companion Diagnostics, by Technology, 2019-2026
Figure 13: Global Market Shares of Companion Diagnostics, by Technology, 2020
Figure 14: Global Market for Companion Diagnostic Technologies, by Region, 2019-2026
Figure 15: Global Market Shares of Companion Diagnostic Technologies, by Region, 2020
Figure 16: Global Market for Immunohistochemistry CDx, by Region, 2019-2026
Figure 17: Global Market for In Situ Hybridization CDx, by Region, 2019-2026
Figure 18: Global Market for Polymerase Chain Reaction CDx, by Region, 2019-2026
Figure 19: Global Market for Next-Generation Sequencing CDx, by Region, 2019-2026
Figure 20: Global Market for Genotyping CDx, by Region, 2019-2026
Figure 21: Global Market for Other CDx Technologies, by Region, 2019-2026
Figure 22: Global Market for Companion Diagnostic Services, by Region, 2019-2026
Figure 23: Global Market for Companion Diagnostics, by Application, 2019-2026
Figure 24: Global Market Shares of Companion Diagnostics, by Application, 2020
Figure 25: Global Market for Companion Diagnostic Applications, by Region, 2019-2026
Figure 26: Global Market Shares of Diagnostic Applications, by Region, 2020
Figure 27: Global Market for Companion Diagnostics in Cancer Applications, by Region, 2019-2026
Figure 28: Global Market for Companion Diagnostics in Cancer Applications, by Type, 2019-2026
Figure 29: Global Market Shares of Companion Diagnostics in Cancer Applications, by Cancer Type, 2020
Figure 30: Global Market for Companion Diagnostics in Pharmacogenetic Applications, by Region, 2019-2026
Figure 31: Global Market for Companion Diagnostics in Cystic Fibrosis Applications, by Region, 2019-2026
Figure 32: Global Market for Companion Diagnostics in HIV Applications, by Region, 2019-2026
Figure 33: Global Market for LDT-CDx, by Application, 2019-2026
Figure 34: Perspective of Different Stakeholders in CDx Market
Figure 35: Companion Diagnostic Business Models
Figure 36: Global Market Shares of Leading Developers of IHC Companion Diagnostics, 2020
Figure 37: Global Market Shares of Leading Developers of ISH Companion Diagnostics, 2020
Figure 38: Global Market Shares of Leading Developers of PCR Companion Diagnostics, 2020
Figure 39: Global Market Shares of Leading Developers of NGS Companion Diagnostics, 2020
Figure 40: Global Market Shares of Leading Developers of Genotyping Companion Diagnostics, 2020
Figure 41: Global Market Shares of Leading Developers of Other Companion Diagnostics, 2020
Figure 42: Share of Patents Issued for Companion Diagnostics, by Year, 2018-June 2021
Figure 43: Patents Issued for Companion Diagnostics, by Application, 2018-June 2021
Figure 44: Patents Issued for Companion Diagnostics, by Assignee, 2018-June 2021
Figure 45: Clinical Trials in Companion Diagnostics, by Type of Study
Figure 46: Clinical Trials in Companion Diagnostics, by Status
Figure 47: Clinical Trials in Companion Diagnostics, by Phase
Figure 48: Clinical Trials in Companion Diagnostics, by Technology
Figure 49: Clinical Trials on Companion Diagnostics, by Application
Figure 50: Share of Clinical Trials in Companion Diagnostics, by Therapeutic Area
Figure 51: SWOT Analysis of the Global Companion Diagnostics Market
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories Inc.
  • Asuragen Inc.
  • Cerba Research
  • Foundation Medicine Inc.
  • Invivoscribe, Inc.
  • Qiagen Gmbh

Pharmacotherapy, as we know it, is undergoing a dramatic transition. The growing knowledge that pharmacotherapy can be highly variable from one patient to another, largely driven by the patient’s genetic and phenotypic heterogeneity, has given rise to the concept of personalized or precision therapy. Further, advances in the research and development of novel molecular biomarkers that point to single gene variations responsible for disease identification and prognosis have aided in the development of companion diagnostics (CDx) tests. A particular application of CDx is in the treatment decision process - that is, to guide the use of targeted drugs.


The employment of CDx has seen extensive adoption in the field of cancer. The development of targeted therapies that rely on specific genetic biomarkers have given a boost to the use of CDx tests that are being increasingly employed to identify the likely responders and non-responders of those therapies.This is exemplified by the 45 FDA-approved CDx and thousands of other lab-developed tests (LDTs) that are available from small- to medium-sized diagnostic laboratories. In fact, many leading specialized laboratories - namely, LabCorp, Quest Diagnostics, Myriad Genetics, Foundation Medicine, ARUP Laboratories, NeoGenomics and many others - are working towards the development of precision medicine-directed CDx assays.


Since they benefit patients directly, CDx are proving to be efficient cost-saving tools for drug developers, healthcare systems and payers alike. Several studies and industry expert reviews have highlighted the billions of dollars’ worth of savings that are possible due to the use of CDx in medical systems. Driven by their potential applications in clinical studies and benefits for patient populations, the CDx are gaining adoption in other disease areas as well, including neurological diseases and cardiovascular diseases, as well as potential decision-making tools for novel therapies like gene and cell therapies, among others.


A leading driver of the global CDx market is the strong collaboration and partnership environment witnessed within pharma and diagnostic developers. Several mergers and acquisitions in recent years have been focused on expanding technical expertise in the precision diagnostics sector, next-generation sequencing (NGS) assays and liquid biopsy, all of them offering opportunities in the CDx development sector. The U.S. has been on the forefront of this market with strong support from the FDA, which encourages the adoption of state-of-the-art diagnostic methods and has extended support for the co-development of drugs with their CDx. Other countries, including some in Europe and several in the Asia-Pacific region, are also updating or establishing their in vitro diagnostics (IVD) regulations to adopt CDx. The reimbursement situation has also seen a positive trend in this market, with many public systems providing coverage for CDx, including NGS multiplex assays.


However, certain challenges for this market remain. The lack of coordination and misaligned financial motivations for pharma and diagnostic developers have led to a slower-than-expected development in the CDx sector. High costs of development, need for regulatory approvals and strong competition from the LDTs have been the major challenges.


Note: Product cover images may vary from those shown
  • Abbott Laboratories Inc.
  • Abnova Corp.
  • Adaptive Biotechnologies Corp.
  • Advanced Cell Diagnostics Inc.
  • Agilent Technologies Inc.
  • Almac Group Ltd.
  • Amoy Diagnostics Co., Ltd.
  • Arup Laboratories
  • Asuragen Inc.
  • Autogenomics Inc. (Acquired By Prescient Medicine)
  • Biocartis Nv
  • Biodesix, Inc.
  • Biofluidica
  • Biomerieux Sa
  • Cerba Research
  • Circulogene
  • Clinical Micro Sensors Inc. (Now Genmark Diagnostics Inc.)
  • Exact Sciences Corp.
  • Exosomedx, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Foundation Medicine Inc.
  • Guardant Health Inc.
  • Hologic Inc.
  • Icon Plc
  • Illumina Inc.
  • Invivoscribe, Inc.
  • Leica Biosystems (Division Of Leica Microsystems Inc.)
  • Luminex Molecular Diagnostics Inc. (Luminex Corp.)
  • Maze Therapeutics
  • Monogram Biosciences Inc. (Part Of Labcorp)
  • Myriad Genetics Inc.
  • Neogenomics Laboratories
  • Prometheus Biosciences
  • Qiagen Gmbh
  • Quest Diagnostics Inc.
  • Resolution Bioscience Inc.
  • Resonance Health Ltd.
  • Siemens Healthineers Ag
  • Spartan Bioscience Inc.
  • Sysmex Corp.
  • Thermo Fisher Scientific Inc.
  • Trimgen Corp.
  • Vela Diagnostics Inc.
Note: Product cover images may vary from those shown